L. Daniel Browne
2015
In 2015, L. Daniel Browne earned a total compensation of $3.8M as President and Chief Executive Officer at Revance Therapeutics, a 58% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $278,355 |
|---|---|
| Option Awards | $2,309,582 |
| Salary | $482,000 |
| Stock Awards | $706,005 |
| Total | $3,775,942 |
Browne received $2.3M in option awards, accounting for 61% of the total pay in 2015.
Browne also received $278.4K in non-equity incentive plan, $482K in salary and $706K in stock awards.
Rankings
In 2015, L. Daniel Browne's compensation ranked 2,351st out of 13,638 executives tracked by ExecPay. In other words, Browne earned more than 82.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,351 out of 13,638 | 83rd |
Division Manufacturing | 842 out of 5,190 | 84th |
Major group Chemicals And Allied Products | 304 out of 1,854 | 84th |
Industry group Drugs | 240 out of 1,528 | 84th |
Industry Pharmaceutical Preparations | 188 out of 1,182 | 84th |
Source: SEC filing on March 24, 2017.
Browne's colleagues
We found two more compensation records of executives who worked with L. Daniel Browne at Revance Therapeutics in 2015.